RxDoctor Payments DataLook up a doctor →

Janice McAlister, NP

Nurse Practitioner · Atlanta, GANPI 1164566253

Payments from drug & device makers

$241,334in general payments, 2019–2025

Across 682 payments — averaging $353.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$175K
  • Esperion Therapeutics, Inc.$31K
  • Chiesi USA, Inc.$13K
  • Novartis$9K
  • Amryt Pharma Holdings Ltd$8K
  • Merck$4K
  • plus $1K from 16 others
$4,145in research payments, 2019–2025

Across 1 payment — averaging $4144.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$4K

What the payments were for

  • Consulting fees$11,7275%
  • Speaking & faculty fees$146,40566%
  • Travel & lodging$46,90921%
  • Food & beverage$15,6187%
  • Education$200%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$241,334 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$2,377,662
Medicare patients
785
Services billed
189,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab1,881$2,501,183
EvkeezaEvinacumab-Dgnb13$630,040
Praluent PenAlirocumab358$445,770
NexletolBempedoic Acid146$78,025
NexlizetBempedoic Acid/Ezetimibe89$57,517
VascepaIcosapent Ethyl80$49,781
EliquisApixaban20$32,708
Repatha SyringeEvolocumab23$32,603
EntrestoSacubitril/Valsartan11$21,996
Ezetimibe813$19,302
JardianceEmpagliflozin16$14,353
LivaloPitavastatin Calcium12$7,620
Rosuvastatin Calcium480$5,439
Icosapent Ethyl20$5,319
Pitavastatin Calcium13$4,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Evkeeza$64$630,04013 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$31,074$135,542235 claims
PfizerEliquis$76$32,70820 claims
NovartisEntresto$8,602$21,99611 claims
Boehringer IngelheimJardiance$50$14,35316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →